180 related articles for article (PubMed ID: 38364396)
1. Retrospective Analysis of the Effect of Comorbid Atopic Dermatitis on the Treatment Response to Topical Immunotherapy in Pediatric Alopecia Areata Patients.
Gök AM; Aşkın Ö; Serdaroğlu S; Kutlubay Z
Dermatol Pract Concept; 2024 Jan; 14(1):. PubMed ID: 38364396
[TBL] [Abstract][Full Text] [Related]
2. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Kagami S; Kishi Y; Hino H
J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
[TBL] [Abstract][Full Text] [Related]
3. A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based on clinical studies.
Behrangi E; Roohaninasab M; Sadeghzadeh-Bazargan A; Najar Nobari N; Ghassemi M; Seirafianpour F; Goodarzi A; Dodangeh M
J Cosmet Dermatol; 2022 Jul; 21(7):2727-2741. PubMed ID: 34606676
[TBL] [Abstract][Full Text] [Related]
4. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
[TBL] [Abstract][Full Text] [Related]
5. Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance.
Weise K; Kretzschmar L; John SM; Hamm H
Dermatology; 1996; 192(2):129-33. PubMed ID: 8829494
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries.
Vañó-Galván S; Egeberg A; Piraccini BM; Marwaha S; Reed C; Johansson E; Durand F; Bewley A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):1027-1037. PubMed ID: 38509379
[TBL] [Abstract][Full Text] [Related]
7. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata.
Ito T; Kageyama R; Nakazawa S; Honda T
Exp Dermatol; 2020 Aug; 29(8):726-732. PubMed ID: 32533873
[TBL] [Abstract][Full Text] [Related]
8. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y
J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
[TBL] [Abstract][Full Text] [Related]
9. Allergen-specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient.
Kwon IJ; Park JW; Kim SM; Lee KH; Park CO
J Dermatol; 2023 Oct; 50(10):1353-1356. PubMed ID: 37248786
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy of Dupilumab in Alopecia Areata.
Kulkarni M; Rohan CA; Travers JB; Serrao R
Am J Case Rep; 2022 Jun; 23():e936488. PubMed ID: 35726185
[TBL] [Abstract][Full Text] [Related]
11. [Hair growth with dupilumab in alopecia areata universalis and atopic dermatitis].
Reinhold L; Lange K; Lindhof H; Homey B; Firouzi-Memarpuri P
Dermatologie (Heidelb); 2022 Jul; 73(7):556-559. PubMed ID: 34609537
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Severity of Alopecia Areata.
You HR; Kim SJ
Ann Dermatol; 2017 Oct; 29(5):565-570. PubMed ID: 28966512
[TBL] [Abstract][Full Text] [Related]
13. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians.
Tan E; Tay YK; Goh CL; Chin Giam Y
Int J Dermatol; 2002 Nov; 41(11):748-53. PubMed ID: 12452996
[TBL] [Abstract][Full Text] [Related]
14. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
Lee S; Kim BJ; Lee YB; Lee WS
JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
[TBL] [Abstract][Full Text] [Related]
15. Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation.
Losol E; Şentürk N
Dermatol Ther; 2021 Jan; 34(1):e14726. PubMed ID: 33377267
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.
Wu SZ; Wang S; Ratnaparkhi R; Bergfeld WF
Pediatr Dermatol; 2018 Nov; 35(6):817-820. PubMed ID: 30338548
[TBL] [Abstract][Full Text] [Related]
17. Topical immunomodulation with diphenylcyclopropenone for alopecia areata: the Lebanese experience.
El Khoury J; Abd-el-Baki J; Succariah F; Abbas O; Kibbi AG; Kurban M
Int J Dermatol; 2013 Dec; 52(12):1551-6. PubMed ID: 24134785
[TBL] [Abstract][Full Text] [Related]
18. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
19. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
Chua SH; Goh CL; Ang CB
Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic management in paediatric alopecia areata: A systematic review.
Waśkiel-Burnat A; Kołodziejak M; Sikora M; Stochmal A; Rakowska A; Olszewska M; Rudnicka L
J Eur Acad Dermatol Venereol; 2021 Jun; 35(6):1299-1308. PubMed ID: 33630354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
